Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: An analysis from the Improve SCA trial.

Reece HolbrookLucas HigueraKael WherryDave PhayYu-Cheng HsiehKuo-Hung LinYen-Bin Liu

Published in: PloS one (2020)

ICD therapy compared to no ICD therapy is cost-effective in the whole PP population and highly cost-effective in the subset 1.5PP population in Taiwan.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
clinical trial
randomized controlled trial
study protocol
prognostic factors
peritoneal dialysis
phase iii
phase ii
open label